Shopping Cart 0
Cart Subtotal
USD 0

Imprimis Pharmaceuticals Inc (IMMY) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Imprimis Pharmaceuticals Inc (IMMY)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless Therapy formulations and topical LessDrops formulations. Its Dropless Therapy formulations include injectable Tri-Moxi and Tri-Moxi-Vanc formulations that eliminate the need for eye drops following ocular surgery; and LessDrops include topical eye drop formulations Pred-Moxi and Tri-Moxi for patients following LASIK, cataract, and other ocular surgeries. Imprimis also commercializes heparin and alkalinized lidocaine (Hep-Lido-A or HLA) formulations for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of peyronie's disease. The company markets its products through distributors and compounding pharmacies. Imprimis is headquartered in San Diego, California, the US.

Imprimis Pharmaceuticals Inc Key Recent Developments

May 15,2018: Surface Pharmaceuticals Announces USD 20 Million Series A Financing from Flying L Partners

May 15,2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results

Apr 10,2018: Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting

Mar 27,2018: Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation

Mar 08,2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Imprimis Pharmaceuticals Inc-Key Facts 6

Imprimis Pharmaceuticals Inc-Key Employees 7

Imprimis Pharmaceuticals Inc-Key Employee Biographies 8

Imprimis Pharmaceuticals Inc-Major Products and Services 9

Imprimis Pharmaceuticals Inc-History 10

Imprimis Pharmaceuticals Inc-Company Statement 13

Imprimis Pharmaceuticals Inc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 16

Company Overview 16

Imprimis Pharmaceuticals Inc-Business Description 17

Imprimis Pharmaceuticals Inc-Corporate Strategy 18

Imprimis Pharmaceuticals Inc-SWOT Analysis 19

SWOT Analysis-Overview 19

Imprimis Pharmaceuticals Inc-Strengths 19

Imprimis Pharmaceuticals Inc-Weaknesses 20

Imprimis Pharmaceuticals Inc-Opportunities 21

Imprimis Pharmaceuticals Inc-Threats 22

Imprimis Pharmaceuticals Inc-Key Competitors 23

Section 3-Company Financial Ratios 24

Financial Ratios-Capital Market Ratios 24

Financial Ratios-Annual Ratios 25

Performance Chart 27

Financial Performance 27

Financial Ratios-Interim Ratios 28

Financial Ratios-Ratio Charts 29

Section 4-Company's Lifesciences Financial Deals and Alliances 30

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31

Imprimis Pharmaceuticals Inc, Recent Deals Summary 32

Section 5-Company's Recent Developments 33

May 15, 2018: Surface Pharmaceuticals Announces USD 20 Million Series A Financing from Flying L Partners 33

May 15, 2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results 34

Apr 10, 2018: Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting 35

Mar 27, 2018: Imprimis Pharmaceuticals Issued Composition Patent for Non-Opioid Conscious Sedation Formulation 36

Mar 08, 2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results 37

Mar 06, 2018: Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations 38

Nov 14, 2017: Imprimis Pharmaceuticals Announces Third Quarter 2017 Results 39

Oct 24, 2017: Imprimis Launches Surface Pharmaceuticals Subsidiary 41

Oct 19, 2017: Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis 42

Oct 02, 2017: Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy Formulations 43

Section 6-Appendix 44

Methodology 44

Ratio Definitions 44

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Imprimis Pharmaceuticals Inc, Performance Chart (2013-2017) 27

Imprimis Pharmaceuticals Inc, Ratio Charts 29

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31


List Of Table

List of Tables

Imprimis Pharmaceuticals Inc, Key Facts 6

Imprimis Pharmaceuticals Inc, Key Employees 7

Imprimis Pharmaceuticals Inc, Key Employee Biographies 8

Imprimis Pharmaceuticals Inc, Major Products and Services 9

Imprimis Pharmaceuticals Inc, History 10

Imprimis Pharmaceuticals Inc, Subsidiaries 14

Imprimis Pharmaceuticals Inc, Key Competitors 23

Imprimis Pharmaceuticals Inc, Ratios based on current share price 24

Imprimis Pharmaceuticals Inc, Annual Ratios 25

Imprimis Pharmaceuticals Inc, Annual Ratios (Cont...1) 26

Imprimis Pharmaceuticals Inc, Interim Ratios 28

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31

Imprimis Pharmaceuticals Inc, Recent Deals Summary 32

Currency Codes 44

Capital Market Ratios 44

Equity Ratios 45

Profitability Ratios 45

Cost Ratios 46

Liquidity Ratios 46

Leverage Ratios 47

Efficiency Ratios 47

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Imprimis Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Trevena Inc

Omeros Corp

Johnson & Johnson

InSite Vision Inc

Bausch & Lomb Inc

Abbott Medical Optics Inc